Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Effectively we have had radio silence from RM since February last year - what little that has come out, notably at last year's agm has been laughable in it's paucity.
As one who met and spoke personally with RM several times when he was doing the rounds at the many investor shows, it was clear to me that he lived and breathed Synairgen and his enthusiasm was contagious. Consequently, I over-invested and never took any profits on the way up because of his enthusiastic personality. I have a colossal loss.
I would dearly love there to be some positive conclusion or announcement next week but on the experience of these past 12 months I am not hopeful. If that is the case, if I were RM, the honourable thing would be to resign and let others shake out a path that promotes the undoubted benefits that I believe SNG001 does possess.
Ecologist - I think you'll find that is a Belgian pharmacy business but language is French. And as for discounts - at the current high product selling price, a discount isn't really a problem - it's early days for Cooper in assessing what the market will bear in price.
I would have liked to see the sp higher at this stage - at least around the 75p level based on the strong indications after the Belgium launch. Remember it's been a whole 2 years since we had the approx 85p spike following the announcement of the CE marking. It then fell back relatively quickly to around 50p and stabilised there for a while - now we're at last back to those levels. Unfortunately, Barder's always been playing a long game - whether that's by accident or design (I think accident) and he'll believe he's been right all the way along. Remember he has a very large shareholding, never mind his options.
In my opinion, we will definitely see another spike once the FDA approves it as an OTC product but the fact that the sp is where it is now means the sp will only respond in future to actual details of sales - something I don't think we'll get for a good while.
I first purchased FUM over 10 years ago but around 60p - fortunately I bought in again when they did the 7p placing which Lombard Odier supported big time - but I think we still have to be patient as to sp growth if FUM stays independent. The quickest way we'll do really well with FUM is, in my opinion, a buyout - something I'm hoping for.
I can't agree on the Consolidation - it's the wrong move right now - experience of other consolidations have all been negative in the early phases as large holders take advantage of the better initial marketability of the stock.
If only the BoD took onboard that the real problems are lack of regular updates on what is going on in Marketing/contracts with the likes of Boots etc. There is effectively nothing concrete being announced.
It’s a complex RNS today no doubt about that. Once again though the big positive is the speedy updates that Paul Dolan announces. And at last great news of the 50000 hectares the Gabon government has made available to start the carbon capture project which will be self financing. It’s success will lead to more business.
Woodbois has shown that it can be a trusted partner in Gabon and will continue to grow this much needed business that provides employment and social cohesion.
Jamrock - I don’t know who you’re confusing me with but I’ve said none of the things you accuse me of. You’ve been constantly ramping this share despite it falling in value by a huge percentage. Frankly your arguments to justify this are ridiculous.
You apparently have multi-millions of shares and have never sold any and yet your current average is close to the current low. I would have thought your average is more likely to be above 2p meaning you are nursing losses of many, many tens of thousands of pounds.
Let’s keep our analysis of MHC rational and not be blinded by wishful thinking.
Jamrock - your repeated comments are like a broken record - sometimes it’s better to let time go by without resorting to daily ramping.
I’ve analysed why the shareprice is where it is- and that’s because ‘saint’ Penny is not performing as you keep telling us she is. The message we hear from her has changed (ie last June’s launch of 5 wellness products we now learn we’re only a ‘Soft Launch’). Her ‘excited’ intention to tell us of yet newer products in 2022 4th quarter never happened.
These are the reasons why the SP is so low. Massaging the message and missing inferred deadlines are not attributes of a great CEO unfortunately for us.
Jamrock - you must have a lot of money spare - keep encouraging people to use the opportunity to average down. Most don't have those sort of funds and look we're even below where this BoD bought in 2020 at 1.5p before all the hard work they did and then raking in the Covid profits. So, what's it all for ? Just for them to look after themselves ? You agree with everyone but apparently keep adding. Ace comes up with questions for the Meet and was one of the few to actually get them asked - but it was the answers or non-answers that she gave that are the problem and why the share is suffering. It's not as you said "sentiment is bad".
By the way in respect to one of the points you've made several times, I don't see any chance of the Bod buying back shares - if they were to do that I'd say that they've run out of ideas how to grow the business. It's very much a shame that they've seem to have lost the push/urgency to really expand this business for the benefit of all of us.
I can see we're going to have to be patient even longer.
All I'm asking Jamrock and all I'm saying is that we need better news and regular updates - not just the required twice a year 3 to 4 months past the date - and keep to the timelines she herself indicated. These are the very things - and only these things that have caused the drop in shareprice. She can control that without question but she isn't and it is a managerial failing solely of hers.
I don't doubt she has positives but her answers today extracted very little information - that is why I added my disappointment comments at the end of today's shareholder meeting. If she doesn't get the message that more communication is necessary, then we have a long wait before the sp recovers. Remember the sp was under a penny this morning whereas most people's average is 2p plus if they've averaged down but more likely nearer 4p I would guess.
What do you think will happen when the 15 : 1 consolidation takes place on the current status of info - I'll be amazed if it doesn't start falling even more. For a company generating good profits, excessively so 2021 & 2022 the sp should be over 3p plus but it's not going to happen unless she gets a grip on communication.
Surprisingly Ace's questions were all raised at the end of a lightweight presentation which was full of hopes and expectations but very little of substance which will help the shareprice in the near-term.
I have no doubt the company is making progress but it is still on the back of Covid sales. The chairman added a comment that the current sp reflects just the cash in the bank never mind anything else.
My comments to the Board at the end of the presentation were:
"Very disappointed at the amazing absence of any real answers to shareholders questions. No explanation was given as to what was happening to the wellness products that are already supposedly on sale. Yet more products coming to the market apparently soon and yet we have no knowledge as to those already on sale. We were told there would be news in the 4th quarter 2022 and yet no explanation why that timeline was missed. Lack of news or keeping to timelines previously announced is what has driven the sp down - and is totally within the CEO's remit to sort. "
I consider the results disappointing but they were what I was expecting and probably as the market was too. Consolidation sometimes works against and generates further selling.
Reserve judgement until I hear what’s said at the end of day shareholders Meet - although I am pessimistic based on what we’ve seen so far.
It is indeed disappointing OneJagielka - the lack of news from the company on its alternative covid products is the sole problem. If we knew what was happening to sales, or even if there are no sales but we were given some knowledge on what the BoD are going to do about it, then I'm quite sure we wouldn't be seeing these lows.
Adding to my earlier report of today's webinar, we know it was recorded so it may be that will become available to us. During the 1st part, the 3 experts gave examples of some of their case histories and we learned that it isn't just older people with comorbidities but all 3 have seen a significant rise in younger males seeking help. Their ED, if it is such, can actually be more a loss of confidence that they will be able to perform with their partner. Each of the Profs. felt that Eroxon was a safe alternative to stimulate the younger person's confidence and could see a wide take-up from this sector of males. This answer led into a discussion that Eroxon will be bought by younger males seeking an even stronger sexual experience/performance. Prof. Ralph said "definitely - it will be used recreationally".
In the Q & A part, a number of questions centred around the fact that the drug element was found not to be needed and that it was simply Dermasys (ie. the carrier component) that did the work. Prof. Ralph said that he agreed that Eroxon's effects were discovered by accident but the clinical trials clearly showed that it worked and there are plenty of ground-breaking examples in medicine where products were discovered by accident.
Prof. Block said "we don't think of it (Eroxon) as a drug but a device (OTC) that works" "it will be the users that will confirm its usefulness. It's non-toxic, works quickly, a topical therapy. A 1st line therapy" . Mention was made of alternative topical treatments such as Vitaros cream but the panel agreed that users had experienced strong burning sensations whereas not with Eroxon which made it their 1st line therapy in future..
I raised a question why the delay in marketing this to the UK and other European countries. I received a direct answer on the webinar Chat from Ken James of Futura that sales will be commencing in the near future" He wouldn't be drawn as to exactly when but a few moments later during the panel discussion, Prof. Ralph said marketing to the UK is the next month or two.
I'm going to try and be patient because it seems clear to me that as word gets around and pricing stays keen/competitive, whilst it might not help everyone, the clinical trials and today's judgement from the experts means sales are going to be massive. I hope this helps LTHs. GLA
That was the message from Prof David Ralph and echoed by the other two panellists Prof Giraldi and Prof Block. 3 professors of Urology. Todays webinar was overwhelmingly positive and they have no doubt that Eroxon will be the 1st line of treatment for ED.
Moreover they had no doubts this will be used by men seeking better sexual performance.
I have to admit to surprise ndr50 that the close was so low on the trades shown unless there's a large one yet to show. Now we're actually selling Eroxon, this has to be good news for us sooner or later.
GLA